Previous 10 | Next 10 |
home / stock / tltff / tltff news
TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compou...
(NewsDirect) Theralase Technologies Inc. CEO Roger DuMoulin-White, joined Proactive's Stephen Gunnion to discuss the company's third-quarter 2023 operational highlights. The company successfully raised $1.17 million, crucial for advancing its Phase II clinical study targeting non-musc...
2023-11-30 09:42:30 ET More on Theralase Technologies: Historical earnings data for Theralase Technologies Inc. Financial information for Theralase Technologies Inc. For further details see: Theralase Technologies reports results for the nine month period ended S...
TORONTO, ON / ACCESSWIRE / November 29 th , 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compoun...
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("...
TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" ...
TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" P...
Post Study II Monitoring of Response, Optional Maintenance Study II Treatments and Central Pathology Laboratory Review Optimized TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical ...
Theralase®'s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®'s Anti-Cancer Therapy Achieved a Complete Response TORONTO, ON / ACCESSWIRE / October 16, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLT...
Theralase®'s Latest Preclinical Data Supports Combining Immunotherapy Drugs with Theralase® PDCs for Increased Cancer Destruction TORONTO, ON / ACCESSWIRE / October 5, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a...
News, Short Squeeze, Breakout and More Instantly...
Theralase Technologies Inc. Company Name:
TLTFF Stock Symbol:
OTCMKTS Market:
Theralase Technologies Inc. Website:
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs "...
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase ® Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF )( FRA:TTX ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic C...
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs...